- ICH GCP
- Registro degli studi clinici negli Stati Uniti
- Sperimentazione clinica NCT06577025
Uno studio su diverse sequenze di Cilta-cel, Talquetamab in combinazione con daratumumab e teclistamab in combinazione con daratumumab dopo induzione con daratumumab, bortezomib, lenalidomide e desametasone in partecipanti con mieloma multiplo di nuova diagnosi a rischio standard (aMMbition)
Uno studio di Fase 2, in aperto, per valutare l'efficacia e la sicurezza di diverse sequenze di ciltacabtagene Autoleucel (Cilta-cel), Talquetamab SC in combinazione con Daratumumab SC (Tal-D) e Teclistamab SC in combinazione con Daratumumab SC (Tec-D ) Dopo l'induzione con daratumumab, bortezomib, lenalidomide e desametasone (DVRd) in partecipanti con mieloma multiplo di nuova diagnosi a rischio standard
The purpose of this study is to evaluate the rate of response (how effectively treatment is working) with signs of potential cure at 5 years after the start of induction treatment. This is defined as a composite of sustained (at least 2 years) minimal residual disease (MRD) negativity with complete response/stringent complete response (CR/sCR) and a positron emission tomography/computed tomography (PET/CT) scan that does not show any signs of cancer at 5 years. MRD negativity and CR/sCR is defined as no detectable signs of remaining cancer cells after the treatment. This study will also characterize how well the treatments administered work in the study through progression-free survival (PFS). PFS is defined as the length of time during and after the treatment of a disease, that a participant lives with the disease, but it does not get worse.
Panoramica dello studio
Stato
Condizioni
Tipo di studio
Iscrizione (Effettivo)
Fase
- Fase 2
Contatti e Sedi
Luoghi di studio
-
-
-
Melbourne, Australia, 3004
- The Alfred Hospital
-
Melbourne, Australia, 3000
- Peter MacCallum Cancer Centre
-
-
-
-
-
Salvador, Brasile, 41253-190
- IDOR - Regional Bahia
-
São Paulo, Brasile, 01509 900
- Fundacao Antonio Prudente A C Camargo Cancer Center
-
São Paulo, Brasile, 05652 900
- Sociedade Beneficente Israelita Brasileira Hospital Albert Einstein
-
-
-
-
-
Heidelberg, Germania, 69120
- Universitaetsklinikum Heidelberg
-
Tübingen, Germania, 72076
- Universitaetsklinikum Tuebingen
-
Würzburg, Germania, 97080
- Universitatsklinikum Wurzburg
-
-
-
-
-
Madrid, Spagna, 28041
- Hosp. Univ. 12 de Octubre
-
Salamanca, Spagna, 37007
- Hosp Clinico Univ de Salamanca
-
Santander, Spagna, 39008
- Hosp. Univ. Marques de Valdecilla
-
-
-
-
California
-
Duarte, California, Stati Uniti, 91010
- City of Hope
-
San Francisco, California, Stati Uniti, 94143
- University of California San Francisco
-
-
Iowa
-
Iowa City, Iowa, Stati Uniti, 52242
- University of Iowa Hospital and Clinics
-
-
New York
-
New York, New York, Stati Uniti, 10065
- Memorial Sloan Kettering Cancer Center
-
-
North Carolina
-
Charlotte, North Carolina, Stati Uniti, 28204
- Levine Cancer Institute
-
-
Criteri di partecipazione
Criteri di ammissibilità
Età idonea allo studio
Accetta volontari sani
Sessi ammissibili allo studio
Descrizione
Inclusion Criteria:
- Participants with documented new diagnosis of multiple myeloma (MM) according to international myeloma working group (IMWG) diagnostic criteria and with no prior myeloma-directed therapy
- Participants must have standard-risk MM (stage I and II) based on revised International Staging System (R-ISS)
- Participants must be considered fit (score equals to [=] 0) or intermediate-fit (score=1) according to IMWG Frailty Index assessment (based on the Charlson Comorbidity Index, the Katz Activity of Daily Living and the Lawson Instrumental Activities of Daily Living)
- Measurable disease defined as: Serum monoclonal paraprotein (M-protein) level greater than or equal to (>=) 1.0 gram per deciliter (g/dL) (>=10 gram per liter [g/L] for institutions using alternative units) or urine M-protein level >= 200 milligrams per 24 hours (mg/24 hours); Light chain MM without measurable disease in the serum or the urine: Serum immunoglobulin free light chain >=10 milligrams per deciliter (mg/dL) (>=100 mg/L for institutions using alternative units) and abnormal serum immunoglobulin kappa lambda free light chain ratio
- Eastern Cooperative Oncology Group (ECOG) performance status grade of 0 or 1
Exclusion Criteria:
- Any ongoing myelodysplastic syndrome or B-cell malignancy (other than MM). Any history of malignancy, other than MM, which is considered at high risk of recurrence requiring systemic therapy
- Peripheral neuropathy or neuropathic pain of Grade >= 2, as defined by National Cancer Institute (NCI)-Common Terminology Criteria for Adverse Events (CTCAE) version 5.0
- Known active or prior history of central nervous system (CNS) involvement or exhibits clinical signs of meningeal involvement of MM
- Stroke or seizure within 6 months of signing the informed consent form (ICF)
- Plasma cell leukemia at the time of diagnosis or any time thereafter through apheresis (>= 5 percent [%] circulating plasma cells in peripheral blood smears), Waldenstrom macroglobulinemia, polyneuropathy, organomegaly, endocrinopathy, monoclonal protein, and skin changes(POEMS) syndrome, or primary amyloid light chain amyloidosis with associated organ dysfunction
- Presence of high-risk disease features: (a) Cytogenetic high risk lesions by MM fluorescence in situ hybridization (FISH) including deletion 17p (del[17p])/, t(4;14), t(14;16), amplification 1q (amp[1q21]) (>= 4 copies); (b) Presence of 1 or more extramedullary plasmacytomas
- Seropositive for human immunodeficiency virus (HIV)
Piano di studio
Come è strutturato lo studio?
Dettagli di progettazione
- Scopo principale: Trattamento
- Assegnazione: Randomizzato
- Modello interventistico: Assegnazione parallela
- Mascheramento: Nessuno (etichetta aperta)
Armi e interventi
Gruppo di partecipanti / Arm |
Intervento / Trattamento |
|---|---|
|
Sperimentale: Cohort A: DVRd Induction + Tal-D Consolidation + Cilta-cel
Participants will undergo apheresis followed by 4 cycles of DVRd induction (each cycle is of 28 days) and cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release, and completion of induction, participants will begin consolidation with 4 cycles of Tal-D (each cycle is of 28 days), followed by a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days); cilta-cel will be administered 5 to 7 days after the start of the conditioning regimen. |
Talquetamab will be administered subcutaneously.
Altri nomi:
Cilta-cel infusion will be administered intravenously.
Altri nomi:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
Altri nomi:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
|
Sperimentale: Cohort B: DVRd Induction + Cilta-cel + Tal-D and Tec-D Consolidation
Participants will undergo apheresis followed by 4 cycles of DVRd induction and Cilta-cel will be generated from the participants' T-cells selected from the apheresis product. Upon completion of cilta-cel production, product release and completion of induction, participants will begin consolidation with a conditioning regimen (cyclophosphamide and fludarabine daily for 3 days) with infusion of cilta-cel 5 to 7 days after the start of the conditioning regimen. Following cilta-cel infusion, alternating cycles of Tal-D (Cycle 1, 3, 5, and 7) and Tec-D (Cycle 2, 4, 6, and 8) will be started, no earlier than Day 84 and no later than Day 168 post cilta-cel infusion. Each cycle of Tal-D or Tec-D is 84 days which includes an extended treatment-free interval. |
Talquetamab will be administered subcutaneously.
Altri nomi:
Teclistamab will be administered subcutaneously.
Altri nomi:
Cilta-cel infusion will be administered intravenously.
Altri nomi:
Daratumumab will be administered subcutaneously as a part of DVRd induction and Tal-D or Tec-D consolidation.
Altri nomi:
Bortezomib will be administered subcutaneously as a part of induction. Lenalidomide will be administered orally as a part of induction. Dexamethasone will be administered orally as a part of induction. Cyclophosphamide will be administered intravenously as a part of conditioning regimen. Fludarabine will be administered intravenously as a part of conditioning regimen. |
Cosa sta misurando lo studio?
Misure di risultato primarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Rate of Response with Curative Potential
Lasso di tempo: Up to 5 years
|
Rate of Response with curative potential is defined as the percentage of participants with a composite of durable (at least 2 years) minimal residual disease (MRD) (10^-5) negativity with complete response/stringent complete response (CR/sCR) by serology and negative positron emission tomography/computed tomography (PET/CT) imaging at 5-years after start of induction therapy. This includes: negative imaging at 5-year landmark time; MRD-negative status (at 10^-5) in 2 bone marrow examinations that are a minimum of 2 years apart; response of CR or better per the International Myeloma Working Group (IMWG) criteria; no examination showing MRD-positive status or relapse from CR in between assessments. |
Up to 5 years
|
|
Progression Free Survival (PFS) Rate at 3-Year
Lasso di tempo: At 3-year
|
PFS is defined as the time from the date of randomization to either progressive disease (PD), according to the IMWG response criteria, or death, whichever occurs first. |
At 3-year
|
|
PFS Rate at 5-Year
Lasso di tempo: At 5-year
|
PFS is defined as the time from the date of randomization to either PD, according to the IMWG response criteria, or death, whichever occurs first. |
At 5-year
|
Misure di risultato secondarie
Misura del risultato |
Misura Descrizione |
Lasso di tempo |
|---|---|---|
|
Overall response rate (ORR; Partial response [PR] or better)
Lasso di tempo: Up to 5 years
|
ORR (PR or better) is defined as the percentage of participants with best overall response of PR or better according to IMWG response criteria. |
Up to 5 years
|
|
CR or Better Rate
Lasso di tempo: Up to 5 years
|
Rate of CR or better is defined as the percentage of participants with best overall response of CR or better according to IMWG response criteria. |
Up to 5 years
|
|
Very Good Partial Response (VGPR) or Better Rate
Lasso di tempo: Up to 5 years
|
Rate of VGPR or better is defined as the percentage of participants with best overall response of VGPR or better rate according to IMWG response criteria. |
Up to 5 years
|
|
Duration of Response (DOR)
Lasso di tempo: Up to 5 years
|
DOR is calculated among responders (with a PR or better response) from the date of initial documented response (PR or better) to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First Response (TTR)
Lasso di tempo: Up to 5 years
|
Time to response (that is, time to first response) is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for PR or better based on the computerized algorithm per IMWG criteria for those who had PR or better as their best response. |
Up to 5 years
|
|
Duration of CR or Better Response
Lasso di tempo: Up to 5 years
|
Duration of CR or better response is calculated among responders (with a CR or better response) from the date of initial documented response CR or better to the date of first documented evidence of PD as defined according to IMWG criteria or death due to any cause, whichever occurs first. |
Up to 5 years
|
|
Time to First CR or Better Response
Lasso di tempo: Up to 5 years
|
Time to first CR or better response is defined as the time between the date of randomization and the first efficacy evaluation that the participant has met all criteria for CR or better based on the computerized algorithm per IMWG criteria. |
Up to 5 years
|
|
PFS on next line therapy (PFS2)
Lasso di tempo: Up to 5 years
|
PFS2 is defined as time from randomization to progression on the next line of therapy or death, whichever comes first. |
Up to 5 years
|
|
Overall Survival (OS)
Lasso di tempo: Up to 5 years
|
OS is measured from the date of randomization to the date of death due to any cause. |
Up to 5 years
|
|
MRD-negative CR Rate
Lasso di tempo: Up to 5 years
|
MRD-negative CR is defined as the percentage of participants who achieved both CR or better and MRD negativity at a threshold of 10^-5 and 10^-6. MRD-negative CR rate will be evaluated at the first occurrence from induction treatment initiation for participants per IMWG criteria. |
Up to 5 years
|
|
Number of Participants with Treatment-emergent Adverse Events (TEAEs) by Severity
Lasso di tempo: Up to 5 years
|
An Adverse event (AE) is any untoward medical occurrence in a participant participating in a clinical study that does not necessarily have a causal relationship with the pharmaceutical/ biological agent under study. TEAEs are defined as AEs with onset or worsening on or after date of first dose of study treatment. Severity of TEAEs will be graded according to the National Cancer Institute Common Terminology Criteria for Adverse Events (NCI-CTCAE) version 5.0. Severity scale ranges from Grade 1 (Mild) to Grade 5 (death). Grade 1= mild, Grade 2= moderate, Grade 3= severe, Grade 4= life-threatening and Grade 5= death related to adverse events. |
Up to 5 years
|
|
Change from baseline in Health-related quality of life (HRQoL) (symptoms and functioning) using the European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Core 30 item instrument (EORTC-QLQ-C30)
Lasso di tempo: Up to 5 years
|
Change from baseline in participants' HRQoL (symptoms and functioning) as assessed by EORTC-QLQ-C30 will be reported. The EORTC-QLQ-C30 includes 30 items in 5 functional scales (physical, role, emotional, cognitive, social), 1 global health status scale, 3 symptom scales (pain, fatigue, nausea/vomiting), and 6 single symptom items (dyspnea, insomnia, appetite loss, constipation, diarrhea, financial difficulties). The recall period is 1 week ("past week") and responses are reported using a verbal rating scale. The item and scale scores are transformed to a 0-to-100 scale. A higher score represents greater HRQoL, better functioning, and more (worse) symptoms. |
Up to 5 years
|
Collaboratori e investigatori
Investigatori
- Direttore dello studio: Janssen Research & Development, LLC Clinical Trial, Janssen Research & Development, LLC
Studiare le date dei record
Studia le date principali
Inizio studio (Effettivo)
Completamento primario (Stimato)
Completamento dello studio (Stimato)
Date di iscrizione allo studio
Primo inviato
Primo inviato che soddisfa i criteri di controllo qualità
Primo Inserito (Effettivo)
Aggiornamenti dei record di studio
Ultimo aggiornamento pubblicato (Effettivo)
Ultimo aggiornamento inviato che soddisfa i criteri QC
Ultimo verificato
Maggiori informazioni
Termini relativi a questo studio
Termini MeSH pertinenti aggiuntivi
- Malattie vascolari
- Malattia cardiovascolare
- Neoplasie
- Malattie del sistema immunitario
- Neoplasie per tipo istologico
- Malattie ematologiche
- Malattie linfoproliferative
- Disturbi immunoproliferativi
- Neoplasie, plasmacellule
- Disturbi emostatici
- Paraproteinemie
- Disturbi delle proteine del sangue
- Disturbi emorragici
- Malattie emiche e linfatiche
- Mieloma multiplo
- Prodotti chimici organici
- Composti eterociclici, 1-anello
- Composti eterociclici
- Composti eterociclici, 2 anelli
- Composti eterociclici, anello fuso
- Idrocarburi
- Acidi carbossilici
- Composti policiclici
- Piperidine
- Prodotti chimici inorganici
- Incinta
- In gravidanza
- Steroidi
- Composti anelli fusi
- Steroidi, fluorurati
- Senape di fosforamide
- Composti di senape di azoto
- Composti di senape
- Idrocarburi, alogenati
- Fosforamidi
- Composti organofosfori
- Incintadienetrioli
- Acidi boronic
- Acidi, non carbossilici
- Acidi
- Composti di boro
- Pirazine
- Ftalimides
- Acidi ftalici
- Acidi, carbociclico
- Piperidoni
- Isoindoli
- Lenalidomide
- Bortezomib
- Desametasone
- Ciclofosfamide
- fludarabina
- daratumumab
- Talquetamab
Altri numeri di identificazione dello studio
- 54767414MMY2093
- 54767414MMY2093 (Altro identificatore: Janssen Research & Development, LLC)
- 2023-505792-71-00 (Identificatore di registro: EUCT number)
- 2023 (Sovvenzione/contratto NIH degli Stati Uniti)
Piano per i dati dei singoli partecipanti (IPD)
Hai intenzione di condividere i dati dei singoli partecipanti (IPD)?
Descrizione del piano IPD
The data sharing policy of Johnson & Johnson Innovative Medicine is available at innovativemedicine.jnj.com/our-innovation/clinical-trials/transparency. As noted on this site, requests for access to the study data can be submitted through Yale Open Data Access (YODA) Project site at yoda.yale.edu
Informazioni su farmaci e dispositivi, documenti di studio
Studia un prodotto farmaceutico regolamentato dalla FDA degli Stati Uniti
Studia un dispositivo regolamentato dalla FDA degli Stati Uniti
Queste informazioni sono state recuperate direttamente dal sito web clinicaltrials.gov senza alcuna modifica. In caso di richieste di modifica, rimozione o aggiornamento dei dettagli dello studio, contattare register@clinicaltrials.gov. Non appena verrà implementata una modifica su clinicaltrials.gov, questa verrà aggiornata automaticamente anche sul nostro sito web .